Prestige Consumer Healthcare Inc. PBH
46.61
0.96
2.10%
as of 25 Sep
- Market cap
- $2.2B
- P/E
- 13.0×
Follow PBH
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
15.37 | 16.19 | 15.04 | 13.17 |
P/S ratio |
2.75 | 2.68 | 2.64 | 2.03 | |
P/FCF ratio |
11.98 | 11.05 | 11.65 | 9.53 | |
P/Operating CF |
53.22 | 37.73 | 67.04 | 31.69 | |
P/B ratio |
1.68 | 1.61 | 1.52 | 1.17 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.57 | 3.58 | 3.52 | 3.79 | |
EV/EBITDA |
10.92 | 11.16 | 11.18 | 12.92 | |
EV/Operating CF |
15.04 | 14.29 | 14.87 | 16.80 | |
EV/FCF |
15.51 | 14.80 | 15.54 | 17.80 | |
Quick Ratio |
2.36 | 1.81 | 2.12 | 1.80 | |
Current Ratio |
3.70 | 3.11 | 3.57 | 3.23 | |
Net Debt/EBITDA |
10.18 | 10.93 | 11.25 | 31.52 | |
Debt/Assets |
29.41% | 30.11% | 28.96% | 44.54% | |
Debt/Equity |
0.55 | 0.58 | 0.54 | 1.06 | |
Asset Turnover |
0.33 | 0.32 | 0.32 | 0.28 | |
Operating CF/Net income |
1.36 | 1.68 | 0.79 | 2.43 | |
Capex/Depreciation |
(0.26) | (0.38) | (0.59) | (0.40) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.35% | 24.60% | 23.21% | 29.34% | |
Intangible Assets out of Total Assets |
0.82 | 0.82 | 0.82 | 0.85 | |
Share Based Compensation of Revenue |
0.64% | 0.97% | 0.94% | 1.50% | |
Graham Net Nets |
(0.37) | (0.42) | (0.41) | (0.96) | |
Graham Number |
58.31 | 57.23 | 58.76 | 57.11 | |
Earnings Yield |
6.51% | 6.18% | 6.65% | 7.59% | |
Free Cash Flow Yield |
8.35% | 9.05% | 8.58% | 10.49% | |
Revenue per Share |
5.59 | 5.92 | 5.81 | 5.60 | |
Operating CF per Share |
1.17 | 1.64 | 0.88 | 1.49 | |
Capex per Share |
(0.04) | (0.06) | (0.11) | (0.08) | |
Free Cash Flow per Share |
1.13 | 1.57 | 0.78 | 1.41 | |
Cash per Share |
2.43 | 1.30 | 1.32 | 1.88 | |
Shareholders Equity per Share |
37.23 | 38.21 | 38.95 | 40.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
37.23 | 38.21 | 38.95 | 40.38 | |
Free Cash Flow |
55.38 | 75.26 | 37.63 | 67.09 | |
Working Capital |
362.81 | 293.87 | 310.56 | 343.01 | |
Capital Expenditures |
(2.10) | (3.03) | (5.21) | (3.70) | |
Net Current Asset Value |
(1,119.90) | (1,231.86) | (1,175.31) | (2,155.04) | |
EV/EBIT |
11.94 | 12.26 | 12.38 | 14.44 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.01 | |
Net Profit Margin |
15.40% | 16.47% | 19.15% | 10.98% | |
Price to Operating Income |
9.22 | 9.16 | 9.28 | 7.73 | |
| Other line items | |||||
Average Receivables |
181.27 | 178.87 | 193.11 | 177.88 | |
Average Payables |
36.55 | 31.23 | 20.86 | 29.53 | |
Average Inventory |
157.61 | 157.56 | 153.42 | 171.67 | |
Average Assets |
3,379.58 | 3,412.12 | 3,448.27 | 4,000.10 | |
Average Common Equity |
1,778.37 | 1,808.94 | 1,861.21 | 1,886.10 |
Columns are period end dates